http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
오승택(Seong Taek Oh),김동구(Dong Goo Kim),김인철(In Chul Kim) 대한소화기학회 1994 대한소화기학회지 Vol.26 No.1
N/A Tumor markers have proven to be useful in monitoring the effect of therapy and are perti- nent prognostic tools for clinical use. One of these tumor markers CA 19 9, is very useful in assessing patients with gastrointestinal tract malignancy, especially pancreatic cancer. From January 1990 to December 1992, serum concentrations of CA 19 9 in 53 patients with pancreatobiliary tract cancer and 18 non-neoplastic diseases were determined at Kangnam St. Marys Hospital to evaluate the clinical usefulness of this tumor marker. The mean value of CA 19 9 in benign disease(39.4+60.8u/ml) is not significantly elevated compared with cutoff value(37u/ml), but in malignant cancer group, the value (136.4162.2u/ ml) is markedly elevated compared with benign disease(p<0.01). Sensitivity of CA 19 9 at a cutoff of 37u/ml in hepatoma is 37.5%, GB cancer 45.5%, ampulla of Vater cancer 66.7%, CBD cancer 77.8% and pancreatic cancer 100%. CBD and pancreatic cancer have higher than hepa- toma, GB cancer and ampulla of Vater cancer(p<0.01). After operation, a significant fall in serum CA 19 9 value occurs in 13 cases(10 out of 17 resected cases and 3 of 10 bypass cases). But the mean value of resected group(60.2+ 88.4u/ml) is lower than bypass group(155.3+94.8u /ml)(p<0.01). During follow-up period, CA 19-9 value is elevated in 3 out of 17 resected cases. These 3 cases are proved cancer recurrence by other imaging methods. In conclusion, the au- thors consider that CA 19 9 test is valuable for detection of pancreas and CBD cancer, assess- ing response to therapy and evaluating early recurrence. (Korean J Gastroenterol 1994; 26: 175 -180)
오승택 ( Seong Taek Oh ) 대한임상종양학회 2010 Korean Journal of Clinical Oncology Vol.6 No.1
Treatment of colorectal cancer (CRC) has developed considerably over the past 10 years, especially in the areas of targeted therapeutics and biomarker development. Targeted therapies, which include monoclonal antibodies and small molecule inhibitors, directed at the vascular endothelial growth factor pathway and the epidermal growth factor pathway are now key players in the treatment of colorectal cancer. Preclinical and clinical studies have shown that the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are valid therapeutic targets for patients with CRC. This review focuses on the evidence supporting the current role of targeted therapy and the strategy of combining chemotherapy and biological therapy in the treatment of metastatic colorectal cancer.
오승택(Seong Taek Oh) 대한종양외과학회 2005 Korean Journal of Clinical Oncology Vol.1 No.2
대장암의 치료는 수술을 근간으로 하여 다양만 항암화학요법과 방사선치료가 보조적으로 사용되고 있다. 항암화학요법은 5-fluo-rouracil(5-FU)을 근간으로 하는 항암화학요법이 널리 사용되고 있고, 최근 들어 oxaliplatinn, irinotecan과 Capecitabine 같은 새로운 항암제가 도입되면서 진행성 대장암 환자의 생존율이 더욱 증가되고 있다. 또한 암세포의 분자생물학적, 유전자적 특성이 밝혀짐에 따라 다양한 분자표적치료제가 개발되고 있으며, 이중에서도 bevacizumab과 cetuximab이 좋은 결과를 보이고 있다. Bevacizumab은 VEGF에 대한 단클론 항체로 신생혈관 생성을 억제하는 기전을 가진 악제로써, 여러 임상연구에서 진행성 암 환자의 1차 약제로 5-FU/LV 또는 irinotecan과 함께 사용하였을 때 반응률 및 생존율의 향상을 보여주었다. Cutuximab은 세포막 수용체인 EGFR에 대한 단클론 항체로 irinotecan에 내성을 보인 진행성 대장암의 2차 약제로 임상연구들이 진행되어 Cetuximab과 irinotecan을 병합탄 투여한 경우 무병생존율이 증가된다고 보고되고 있다. 분자생물학의 발전에 따라 분자표적치료는 더욱 발전할 것으로 생각되며, 기존의 약제와의 이상적인 병합요법과 치료순서에 대한 연구도 진행되어 암 치료에 신기원을 이룰 수 있을 것으로 생각된다. Colorectal cancer is the fourth most common malignant disease in Korea. Until recently, fluorouracil was the only effective systemic treatment for colorectal cancer. But during the past five years, the Food and Drug Administration has approved four new treatments for advanced colorectal cancer. Two of them (irinotecan and oxaliplatin) are cytotoxic drugs, whereas the other two (bevacizumab and cetuximab) are monoclonal antibodies against molecular targets. Bevacizumab, a humanized antibody directed against the vascular endothelial growth factor, has been examined in combination with chemotherapeutic agents in several clinical trials in patients with advanced colorectal cancer. According to the clinical trial conducted by Hurwitz, the addition of bevacizumab to IFL led to an impressive, statistically significant increase in the rate of response and prolongation in median overall survival. Recently, a statistically significant prolongation in median survival was also reported with the addition of bevacizumab to FOLFOX in patients with advanced colorectal cancer. Cetuximab is a monoclonal antibody against the epidermal growth factor receptor. It appears to be synergistic with irinotecan, even in irinotecan-resistant tumors. The most common side effects of cetuximab is acne-like rash, and the development and severity of it have been correlated with an increased likelihood of an objective response. Additional research will be required to define the optimal selection and scheduling of available cytotoxic and biologic treatment in individually tailored therapeutic strategies.
오승택(Seung-Taek Oh),김병기(Byung-Ki Kim),노대석(Dae-Seok Rho),박성민(Seong-Min Park),박진엽(Jin-Yeop Park) 한국산학기술학회 2014 한국산학기술학회 학술대회 Vol.- No.-
기존의 원자력발전소의 전원공급장치(UPS : Uninterruptible Power Supply)에는 연축전지가 많이 보 급되어 사용되고 있지만, 수명이나 유지보수 측면에서 많은 문제점을 가지고 있다. 또한 일본의 후쿠 시마 원전사고 이후, 원자력발전소에 있어서 비상전원의 안정적 확보와 용량증대의 필요성이 부각되고 있어서, 차세대 전지기술로 각광받고 있는 리튬이온전지로의 교체가 요구되고 있다. 하지만 원전용 전 원공급장치에 리튬이온전지를 적용하기 위한 기술기준이 없으므로, 이에 대한 개발이 필요한 실정이 다. 따라서 본 논문에서는 원전용 전원공급장치에 리튬이온전지를 적용하기 위한 기술기준 개발을 위 하여, 기초자료로 필수적인 원전용 부하특성과 전원공급장치를 분석하였다.